Mircrining the injured heart with stem cellderived exosomes: an emerging strategy of cell-free therapy. by Haider, KH & Aramini, B.
1/6/2020 e.Proofing
https://eproofing.springer.com/journals_v2/printpage.php?token=ka08wweTTmMlo03z9l14m3D53S-ivN8EZmkIqLYfrb0 1/35
Query Details Back to Main Page
1.  The article title in the manuscript “Mircrining” the injured heart with stem cell-derived exosomes:an
emerging strategy of cell-free therapy differs from that in the submission system which is “Mircrining”
the injured heart with stem cell-derived exosomes:an emerging strategy of cell-free therapy”. Please note
that we have followed the manuscript. Please check if correct.
2.  Author names: Please confirm if the author names are presented accurately (given names/initials,
family name). Author 1: Given name: Khawaja Given name: Husnain Family name: Haider Author 2:
Given name: Beatrice Family name: Aramini
3.  Please check if the affiliations are presented correctly.
4.  Please check if edits in the sentence “With scanty evidence regarding their cardiogenic differentiation
in the recipient patients’ hearts post-engraftment, paracrine secretion of bioactive molecules is being
accepted as the most probable underlying mechanism to interpret the beneficial effects of cell therapy.”
retained its intended meaning.
5.  Please check if the keywords are presented correctly.
6.  All instances of “miR-payload” were changed to “miR payload” for consistency. Please check if the
action taken is appropriate and amend if deemed necessary.
7.  Should “International Society Cell Therapy” be changed to “International Society for Cell and Gene
Therapy”? Please check and consider modifying.
8.  Please check if edits in the sentence “These strategies include physical manipulation of cells....”
retained its intended meaning.
9.  Please check if edits in the sentence “There was heterogeneity in the exosomes released by cells in
terms of their size as well as contents which have reported the existence of distinct subpopulations of
exosomes [68].” retained its intended meaning.
10.  Please check if edits in the sentence “Nevertheless, exosome subpopulations expressed exosome-
specific protein markers including tetraspanins, i.e., CD9, CD63, and CD81; biogenesis-related specific
marker proteins, i.e., TSG101 and ALIX; and heat-shock proteins (HSP), i.e., HSP60, HSP70, and
HSP90.” retained its intended meaning.
1/6/2020 e.Proofing
https://eproofing.springer.com/journals_v2/printpage.php?token=ka08wweTTmMlo03z9l14m3D53S-ivN8EZmkIqLYfrb0 2/35
11.  All instances of “myomiRs” were changed to “myo-miRs” for consistency. Please check if the action
taken is appropriate and amend if deemed necessary.
12.  Should all instances of “miRNA” be changed to “miR” to be consistent with the abbreviation of the
term “microRNA”? Please check and consider modifying.
13.  Please check if the figure captions are presented correctly.
14.  Please check if the table is presented correctly.
15.  Authors’ contributions: As per standard instruction, the statement “Both authors read and approved
the final manuscript.” is required in the “Authors’ contributions” section. Please note that this was
inserted at the end of the paragraph of the said section. Please check if appropriate.
16.  Reference [143] was provided in the reference list; however, this was not mentioned or cited in the
manuscript. As a rule, all references given in the list of references should be cited in the main body. Please
provide its citation in the body text.
“Mircrining” the injured heart with stem
cell-derived exosomes: an emerging
strategy of cell-free therapy
AQ1
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0
International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The
Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ )
applies to the data made available in this article, unless otherwise stated.









Sulaiman AlRajhi Medical School AQ3 , Al-Qaseem, Kingdom of Saudi
Arabia
Division of Thoracic Surgery, Department of Medical and Surgical
Sciences, University of Modena and Reggio Emilia, Modena, Italy
Department of Basic Sciences, Sulaiman AlRajhi Medical School, PO Box
777, Al Bukairiyah, 51941 Kingdom of Saudi Arabia
Received: 5 December 2019 / Accepted: 29 December 2019
Abstract
Bone marrow-derived mesenchymal stem cells (MSCs) have successfully
progressed to phase III clinical trials successive to an intensive in vitro and pre-
clinical assessment in experimental animal models of ischemic myocardial injury.
With scanty evidence regarding their cardiogenic differentiation in the recipient
patients’ hearts post-engraftment, paracrine secretion of bioactive molecules is
being accepted as the most probable underlying mechanism to interpret the
beneficial effects of cell therapy. Secretion of small non-coding microRNA (miR)
constitutes an integral part of the paracrine activity of stem cells, and there is an
emerging interest in miRs’ delivery to the heart as part of cell-free therapy to
exploit their integral role in various cellular processes. MSCs also release
membrane vesicles of diverse sizes loaded with a wide array of miRs as part of
their paracrine secretions primarily for intercellular communication and to shuttle
genetic material. Exosomes can also be loaded with miRs of interest for delivery
to the organs of interest including the heart, and hence, exosome-based cell-free
therapy is being assessed for cell-free therapy as an alternative to cell-based
therapy. This review of literature provides an update on cell-free therapy with
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Nearly two decades of bone marrow stem cell (BMSC) research for the treatment of
the infarcted heart has generated encouraging data in experimental animal models
as well as in the clinical settings and shown the safety and effectiveness of the
procedure as an alternative to the contemporary therapeutic modalities [1]. The
transplanted BMSCs attenuate infarct size expansion, prevent left ventricular
remodeling, and preserve the indices of global cardiac function [2]. The much-
purported mechanism that the transplanted BMSCs cross lineage-restriction and
adopt morphofunctionally competent cardiomyocyte phenotype for de novo
myocardial regeneration has been challenged by various research groups [3, 4]. In
the midst of the controversy regarding the differentiation capacity of the
transplanted BMSC, paracrine release of bioactive molecules has emerged as an
alternative and more acceptable mechanism by which stem cells contribute towards
preserved global cardiac function post-transplantation in the infarcted myocardium
[5, 6]. Nevertheless, the paracrine secretome of BMSCs does not possess a distinct
composition; the amount, as well as the composition of the paracrine secretome of
BMSC, is influenced by a multitude of factors encompassing the microenvironment
in which the cells are present to the physical, pharmacological, or genetic
manipulation of the cells [7]. We have also reported that preconditioned
mesenchymal stem cells (MSCs) and MSCs genetically modified to overexpress
microRNA-210 (miR-210) transferred miR-210 to the juxtaposed cardiomyocytes
in a direct co-culture system in vitro as well as to the recipient cardiomyocytes
post-transplantation. Our results vividly showed that transfer of miR-210 occurred
from the transplanted MSCs to cardiomyocyte via gap junctions [8, 9]. We also
observed that the transferred miR-210 initiated survival signaling in the recipient
cardiomyocytes and contributed to their survival upon subsequent exposure to
lethal anoxia.
Encouraging results from the use of paracrine secretions of stem cells in general
and from the BM-derived MSCs in particular have paved the way for cell-free
therapy which is based on the engineering of cells to tailor their secretions to the
therapeutic needs [10, 11]. Figure 1 shows a head-to-head comparison of cell
therapy and cell-free therapy. A step forward in this regard is the use of stem cell-
derived exosomes, either with their intrinsic miR payload or with the manipulated
miR payload of interest for which they are used as carriers for myocardial delivery
[12]. Our review summarizes the advancements in this fast-emerging therapeutic
strategy with immense therapeutic potential and provides a critical appreciation of




A head-to-head comparison of cell therapy and cell-free therapy
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BM-derived MSCs
Bone marrow (BM)-derived mesenchymal stem cells (MSCs) are one of the most
well-characterized and extensively studied cell types in the field of stem cell-based
therapy. They are a heterogeneous group of cells that constitute an integral part of
the stem cell niche in the BM and also support the hematopoietic stem cell (HSC)
niche microenvironment by secreting a plethora of growth factors and cytokines to
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regulate their activity [13, 14]. Given the lack of a consensus marker for
identification, they are generally characterized based on their plastic adherence
properties; tri-lineage differentiation potential, i.e., osteogenic, adipogenic, and
chondrogenic; and surface membrane expression of specific clusters of
differentiation (CD) including CD90 and CD105, besides CD17, CD29, CD44, and
CD106, while lacking in the expression of HSC-specific markers, i.e., CD31,
CD34, CD133, CD14, CD19, and KDR. This is in line with the recommendations of
International Society Cell Therapy (ISCT) to establish uniform criteria for isolation
and purification of MSCs for therapeutic application [15, 16]. MSCs are available
from almost every tissue, i.e., adipose tissue, umbilical cord, dental pulp, etc., but
their isolation from the BM is most favored due to the ease of accessibility and the
requirement of less invasive protocols. The percentage of isolated MSCs from the
BM is 0.001–0.0001% only; however, they can be easily expanded in vitro to obtain
a larger number. It is important to note that MSCs isolated from various species and
various tissues may diverge in the expression of surface markers. They have been
studied in-depth for reparability of the heart besides other clinical applications due
to near-ideal characteristics, i.e., ease of autologous availability and
undifferentiated in vitro expansion, multi-lineage differentiation potential,
immunomodulatory characteristics, and multifactorial mechanisms of myocardial
repair including the release of bioactive molecules as part of their paracrine action
[17].
AQ7
MSCs and their paracrine activity
BM-derived MSCs release a variety of bioactive molecules for intracellular
communication and signaling in their vicinity. The paracrine hypothesis was earlier
proposed for interpretation of therapeutic benefits of stem cell therapy. According
to the paracrine hypothesis, akin to any other cell in the body, stem cells actively
secrete many different substances, i.e., chemokines, cytokines, interleukins, growth
factors, lipids, steroids, nucleotides and nucleic acids, ions, metabolites, etc.
Moreover, the release of microRNAs (miRs) is an integral part of their paracrine
activity which will be discussed further as part of exosomal activity [18]. These
substances are secreted either by conventional or by unconventional pathways in a
regulated or unregulated manner [19]. The composition of secretome (consisting of
the mixture of soluble factors as well as microvesicles) released by each stem cell
type is unique and cell-specific in composition. The composition of the secretome
is also affected by a multitude of extraneous factors including the stem cell donor-
specific factors, i.e., age, health status, comorbidities, tissue source, etc., as these
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factors significantly impact the quality of the donor stem cells as well. It is
pertinent to mention that in vivo spectrum of bioactive molecules released by stem
cells remains oblivious due to the lack of a standard protocol. Single nucleus
capture microdissection combined with high-throughput real-time polymerase chain
reaction (PCR) was performed to elucidate gene expression profile of the
transplanted MSCs in an infarcted mouse heart model of myocardial infarction (MI)
which revealed that the expression profile was comparable with the cells cultured in
vitro [20]. The transplanted cells were rich in VEGF, IGF-1, FGF-2, Ang-1, Ang-2,
PDGF, NGF, BMP-2 & 4, IL6, TGF, and TNF expression in the infarcted hearts as
compared to the normal hearts. This observation also signified the role of
microenvironment as an important determinant of the paracrine expression profile
of a cell. A similar earlier study has shown heterogeneity in the paracrine profile
shown by the different lineages of BM-derived cells wherein single nucleus PCR
revealed higher-level expression of angiogenic growth factors by CD45+
subpopulation as compared to the other sublineages [21].
In vitro profiling of stem cell secretome mostly relies on the conditioned medium
obtained from the cultured cells. Despite extensive efforts, a standard secretome
profile in vitro is lacking that could be used as a reference as the composition of the
secretome fluctuates in response to multitude of factors including the type of the
stem cell, cell source, its differentiation status, and microenvironmental cues which
are duly responded by the cells in order to maintain cellular homeostasis. For
example, secretome of naïve undifferentiated BM-derived MSCs is richer in pro-
angiogenic factors as compared to the secretome of their osteogenic and
chondrogenic derivatives [22]. Similarly, secretome of MSCs subjected to ischemia
varied in VEGF expression between the cells isolated from C57/BL6 and Balb/c
mouse strains [23]. This difference was also evident from the angiogenic response
observed when the cells from the two sources were engrafted in an experimental
model of hind-limb ischemia. The authors attributed the difference between the
angiogenic reparability of the cells and the genetic makeup of the donor animals
used as a cell source, i.e., polymorphism in the cis-acting VEGF gene in Balb/c
mice on chromosome 17 significantly reduces VEGF gene transcription as well as
expression under ischemic conditions. A recently published study has reported that
MSCs subjected to hypoxia were richer in pro-inflammatory and pro-angiogenic
cytokine expression (especially in VEGF-A expression) as compared to their
counterparts cultured under normoxia [24]. MSC secretome profile changes
drastically in 3D culture as compared to the 2D culture conditions as the former
mimics more closely to their natural habitat [25, 26]. The secretome profile changes
thus observed have been attributed to the expression of desirable phenotype of the
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cells due to spheroid formation thus rendering a more desired physiological
microenvironment. Priming 3D-cultured human MSCs with interleukin-1 enhanced
the paracrine release of GCSF, VEGF, and interleukin-1 receptor antagonist (IL-
1Ra). Protein array showed more potent immune profile which was required to
orchestrate an effective tissue repair [27]. The effect of culture surface topology
and microenvironment significantly alters the morphology of the cultured cells
besides altering their cellular activity including the secretome profile [28]. The
authors used a high-throughput tool TopoWell Plate with unique topographies to
quantify the effect of surface topology in terms of cytokine and growth factor
release. The results of the study showed a significant relationship between cytokine
and growth factor secretion and the cell shape adaptations.
Various strategies are being developed to prime/precondition the cells such that
their secretome can be manipulated to achieve the desired composition for cell-free
therapy. These strategies include physical manipulation of cells, i.e., ischemic
preconditioning [29, 30, 31, 32], hypoxic preconditioning, heat-shock treatment
[33, 34, 35], electrical treatment and mechanical stimulation [36, 37], shockwave
treatment [38, 39], and mechanical stress [40]; pharmacological treatment of cells
with preconditioning agents, i.e., diazoxide, statins, and PDE5 [41, 42, 43, 44]; pre-
treatment of cells with growth factors and cytokines, i.e., IGF-I, SDF-1, TGF-b, and
IL-1 [45, 46, 47, 48, 49]; treatment with cell lysate [50]; or combined treatment
using more than one of these strategies [51]. Besides, genetic manipulation via
single or multiple gene modification of cells encoding for growth factors,
cytokines, pro-survival molecules, or a combination of growth factors with pro-
survival factors has been extensively studied to modulate stem cell’s paracrine
behavior [52, 53, 54, 55, 56, 57, 58]. While elucidating the mechanism underlying
the improved paracrine activity of MSCs with concomitant overexpression of Akt
and Ang-1, we observed significant induction of HIF-1α and its dependent array of
angiogenic growth factors [59]. Such manipulation of the cells not only enhanced
their paracrine activity but also altered their culture characteristics as well as
resulted in stable therapeutic benefit post-engraftment in the experimental animal
models of myocardial infarction [60, 61]. The paracrine factors released from the
preconditioned cells initiate diverse signaling pathways. Besides contributing to
cytoprotection of the recipient cardiomyocytes, they also support the survival of the
transplanted stem cells, initiate an endogenous angiogenic response, and create a
favorable concentration gradient of the secreted growth factors to promote
endogenous stem cell mobilization, homing-in, and retention in the infarcted




Exosomes as part of paracrine activity
Exosomes are one of the many subtypes of lipid membrane nano-sized vesicles
ranging from 50 to 200 nm in size and secreted by various cell types for
intercellular cross-talk [64, 65]. Characterized by the lipid bilayer structure,
exosomes are quite distinct from microvesicles that are much larger in size while
exosomes differ from apoptotic bodies which are derived from apoptotic cells and
contain nuclear fragments [66]. Proteomic analysis showed that MSC-derived
exosomes retained critical surface markers, receptors, and functional proteins akin
to their mother cells which provided comprehensive understanding of the
mechanism by which MSC-derived exosomes contributed towards tissue repair and
regeneration [67]. There was heterogeneity in the exosomes released by cells in
terms of their size as well as contents which have reported the existence of distinct
subpopulations of exosomes [68]. The exosome subpopulations, categorized as low-
density (LD) and high-density (HD) exosomes, were observed during sucrose
density gradient centrifugation. Nevertheless, exosome subpopulations expressed
exosome-specific protein markers including tetraspanins, i.e., CD9, CD63, and
CD81; biogenesis-related specific marker proteins, i.e., TSG101 and ALIX; and
heat-shock proteins (HSP), i.e., HSP60, HSP70, and HSP90. Raman spectral
analysis of individual exosomes isolated from a single cell line showed high-level
spectral variability in terms of cholesterol, protein, lipid, and cytosolic contents
[69]. The authors of this study also compared the analysis of exosomes from eight
different cell lines and observed at least four subpopulations of exosomes were
conserved across the cell lines thus pointing towards their preserved biological
functionality. On functional basis, exosomes are responsible for signal transduction
affecting the physiological and pathological working of cells besides being part of
antigen presentation and immune response mechanisms [70]. Exosome
heterogeneity may also be attributed to differences in the isolation protocols, their
secreting cell source, and methods used for their characterization [71]. Moreover,
the efficiency of exosome production has been reported as inversely related with
the developmental maturity of the donor of MSCs. In a direct comparison of MSCs
derived from ESCs, fetal tissue, and umbilical cord, it was observed that the ESC-
derived MSCs were most efficient while umbilical cord-derived MSCs were least
efficient in exosome production thus underpinning an inverse relationship between
the developmental stage and rate of exosome production [72].
AQ9
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Originating as intraluminal vesicles, exosomes are released extracellularly when an
intermediate endocytic compartment in the cell fuses with the plasma membrane
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and gets extruded into the extracellular milieu [73]. Although the exact mechanism
underlying their biogenesis remains an area of intense investigation, it is generally
considered as an “endosomal sorting complex required for transport” (ESCRT)-
dependent or ESCRT-independent mechanism [74]. Besides, ceramide has been
implicated in the biogenesis and secretion of exosomes. At molecular levels, Rab
proteins, i.e., Rab11, Rab27, and Rab35, are involved in intracellular compartment
trafficking and ultimately secretion of exosomes with an as yet unconfirmed role of
SNARE proteins [75]. Once released from the cells, exosomes fuse with the
recipient cell membrane and get internalized to deliver their payload. Our review is
more focused on the exosome-based mircrine activity of MSCs of BM origin with
focus on their potential use in cardiovascular applications as part of cell-free
therapy which is being extensively studied in the context of regenerative and
reparative strategies for the infarcted heart [76, 77].
Composition of exosome-based mircrine activity of
MSCs
The exosomal payload includes a variety of biomolecules such as DNAs, mRNAs,
miRs, non-coding RNAs, proteins, lipids, and other cellular metabolites. Since the
publication of the first report that exosomes can mediate the transfer of genetic
material between two cells [78], many subsequent studies have confirmed that miR
transfer between nearby cells (without cell-to-cell contact) may occur via exosomes
as part of the mircrine activity of the cells [79, 80, 81]. MiRs are small non-coding
RNA molecules which are 18–22 nucleotides in length. They are produced as
inactive precursors in the nucleus which undergo multiple-step processing that
involves enzyme cleavage and subsequent exportation into the cytoplasm. Upon
functional maturity, miRs post-transcriptionally regulate gene expression to affect
multiple cellular functions including cell survival, proliferation, and differentiation.
Nucleic acid content analysis of MSCs’ derived exosomes has revealed the specific
presence of both pre-miRs and miRs as an integral part of the exosomal payload
[82]. A direct comparison of miR expression profile of rodent BM MSCs and their
derivative exosomes revealed a general similarity; however, some miRs which
negatively regulate cardiac function, i.e., miR-130, miR-378, and miR-34, while
others which positively impact cardiac function, i.e., miR-29 and miR-24, were
differentially expressed between them [83]. The similarity between MSCs and their
derivative exosomes in terms of miR profile points to the identical mechanism of
beneficial effects of their therapeutic applicability. Nevertheless, despite extensive
profiling studies, a single standard MSC miR profile is still lacking that can be used
as a reference. It keeps changing even between the cells derived from the same
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tissue but cultured under a different set of culture conditions and differentiation
status of the cells as well as passage number. Therefore, miR profiling of MSCs
only reveals the expression of signature miRs by the cells under a specific set of
conditions. This is akin to the composition of other paracrine secretions of MSCs
which keep changing in response to various extraneous factors in the
microenvironment of a cell. This variability in the exosomal payload of miRNAs
allows the cells to respond to the functional requirements of the cells and their
response to the pathophysiological cues. For example, miR-572 and miR-638 may
be used to distinguish between the early and late passage MSCs in vitro [84].
Similarly, global miR profiling showed 15 miRs showing high-level changes, with
miR-222 and miR-423 showing the most significant contribution during osteogenic
differentiation of MSCs [85]. A direct comparison of the three cell populations
profiled at different osteogenic differentiation states, i.e., naïve, un-manipulated
early-stage, and late-stage osteogenic cells, showed that from amongst the top 50
miRs expressed in these cells, 42 miRs (84%) showed similar expression levels
[86]. From amongst the differentially expressed miRs, the expression of the
negative regulators of osteogenesis including miR-31, miR-144, and miR-221 was
significantly decreased in the exosomes derived from the late-stage differentiating
MSCs. A similar study revealed differential expression of miRs including let-7a,
miR-199b, miR-218, miR-148a, miR-135b, miR-203, miR-219, miR-299-5p, and
miR-302b which increased while miR-221, miR-155, miR-885-5p, miR-181a, and
miR-320c decreased significantly in exosomes derived from MSCs undergoing
osteogenic differentiation until 7 days of observation as compared to the
undifferentiated cells [87]. Microarray analysis also revealed a series of upregulated
miRs, i.e., miR-193a-5p, miR-320c, and miR-92a, in the exosomes derived from
human BM MSCs undergoing chondrogenic differentiation [88].
Akin to differentiation status, tissue source of MSCs has significant bearing on
exosome release and their miRNA contents [89]. Although the authors of the study
found significant similarity in terms of miRNA contents of the exosomes derived
from adipose tissue and BM-derived MSCs, the relative proportion of the most
representative miRNAs was different between MSCs derived from the two distinct
tissue types. This difference was attributed to the cues emanating from their
respective microenvironment. Similar differences have been observed in the
exosomes isolated from embryonic stem cell (ESC)-derived MSCs and adult tissue-
derived MSCs [90]. On the same note, the health status of the MSC donor remains




Manipulation of MSCs to enhance exosomal miRNA
payload
In addition to the development of Good Manufacturing Practice (GMP) grade
protocols to enhance the exosomal activity of MSCs [93], the cells are being
manipulated to modify their exosomal miRNA payload [94]. Various strategies have
been adopted in this regard. For example, the treatment of in vitro cultured MSCs
with ischemic brain extract leads to miR-133-rich exosome release by the cells
[95]. Genetically modified MSCs with an expression plasmid encoding for miR-146
or miR-584 released exosomes rich in their respective miR and were successfully
used to treat glioma in experimental rodent and murine animal models [96, 97].
Overexpression of HIF-1α in MSCs not only increased their rate of exosome
secretion but also altered the miRNA payload of the secreted exosomes from the
genetically modified MSCs. Profiling of exosomes derived from HIF-1α
overexpressing MSCs showed significantly higher presence of miR-15, miR-16,
miR-17, miR-31, miR-126, miR-145, miR-221, miR-222, miR-320a, and miR-424
as compared to control MSCs [94]. From amongst the profiled miRNAs, miR-31
was of most interest in terms of its role in migration and tube formation response
during in vitro angiogenic assay.
MSCs have been manipulated in vitro to alter the expression of various myo-miRs
(myocardium-related miRs) including miR-1, miR-133, miR-208, and miR-499 to
enhance their cardiac differentiation [98, 99, 100]. A recent study has explored an
interesting aspect of myo-miRs regarding their exosome-encapsulated release from
the infarcted heart (except for miR-133 which is partially released in the exosomes)
that gets transferred to the BM mononuclear cells [101]. The recipients’ BM cells
consequently respond by decreasing CXCR4 expression which promotes their
extravasation from the BM into the peripheral circulation to aid in the myocardial
repair process. Peinado et al. have previously reported a similar mechanism in
which melanoma cells metastasize as well as send signals to the BM progenitor
cells to mobilize out from the BM [102]. Similar results have been reported by
other research groups specifying evidence of a dynamic exosomal miR transfer
between the injured cells and stem cells as an integral part of the repair process.
The recipient stem cells in turn either reprogram their phenotype to become part of
the injured tissue or release exosome-encapsulated genetic information which
facilitates the surviving cells in the injured tissue to re-enter into cell cycle and
become part of the repair process [82, 103]. These data support the hypothesis that
microvesicles emanating from the injured tissue cells send “SOS” signals to
activate stem cells and ensure their participation in the repair process. We have also
reported their role as important regulators of the paracrine activity of MSCs [104].
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As stated earlier, myo-miRs have been implicated in the early- and late-stage
development of the heart as well as during physiological and pathological
conditions. For example, myo-miRs show dysregulated expression in MI patients
[105] while downregulation of miR-133a/b has been correlated in MI patients with
ventricular fibrillation [106]. Hence, the transplantation of MSCs with transgenic
miR-133 is cardioprotective for the infarcted heart [107]. MSCs with miR-133
overexpression also show a higher rate of survival under hypoxic culture conditions
as compared to their naïve counterparts. Apart from myo-miRs, various other miRs
have been studied in this regard. MiR-21 with anti-apoptotic activity gets
dysregulated in the exosomes derived from stromal cells in heart failure patients
which significantly impair their regenerative capacity [108, 109]. We have reported
that MSCs modified for miR-210 overexpression, either by preconditioning or by
genetic modification, transferred miR-210 to the adjacent cardiomyocytes in the co-
culture as well as post-transplantation in the infarcted heart. We observed that miR-
210 was transferred to the cardiomyocytes via gap junctions and prevented the
recipient cardiomyocytes’ apoptosis under anoxia during co-culture in vitro as well
as in the infarcted heart post-engraftment [8, 9].
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In continuation of these observations and with the recent emerging interest in
exosomes as safe and efficient mediators of material transfer between cells, an
exosome-based cell-free therapy approach has gained popular acceptance for miR
delivery and manipulation in the cardiovascular settings. Furthermore, exosomes
have emerged as an integral part of the multifactorial underlying mechanism of the
beneficial effects of cell therapy [110]. Incidentally, exosomes derived from various
cell types including CSCs and endothelial cells have been used as part of the cell-
free therapy [111, 112, 113, 114, 115, 116]. Most of the published reports have used
exosomes containing either endogenous or exogenous miR payload. For example,
treatment with MSC-derived exosomes enhanced myocardial cell viability through
activation of PI3/Akt signaling and concomitant increase in ATP thus resulting in
attenuated remodeling in the ischemic heart [115]. A recent study has reported that
MSC-derived exosomes alter the polarization status of M1 macrophages to M2 type
as the underlying mechanism involving miR-182 to attenuate ischemia/ reperfusion
myocardial injury [116]. Moreover, treatment with MSC-derived exosomes also
promoted the angiogenic response that helped in regional blood flow recovery in
the myocardium [117] besides improving the microenvironment in the infarcted
heart by attenuating the ongoing inflammatory response [118].
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MSCs have also been physically or genetically modulated to augment miR payload
in their secreted exosomes thus boosting their therapeutic potential [119, 120].
MSC-derived exosomes are electroporated with the desired miR mimics to enhance
miR payload of interest and later used for treatment. Ma and colleagues have
reported miR-132-rich exosomes to promote angiogenesis in the murine heart
model of MI [121]. In an interesting study, MSC-derived exosomes were used to
precondition tissue cultured cardiac stem cells (CSCs) which enhanced their
myocardial reparability post-engraftment [122]. In vitro characterization of the
preconditioned CSCs showed their proangiogenic ability in a dose-dependent
manner. Profiling of miRNA revealed that a set of miRs was differentially altered in
the preconditioned CSCs (17 miRs increased while 5 showed decreased expression)
that contributed to their enhanced migration, proliferation, and tube formation in
vitro. Zilun et al. genetically modified MSCs using lentiviral vectors encoding for
miR-181a and subsequently used the derivative exosomes to treat ischemia-
reperfusion injury-induced inflammatory response in murine myocardium [120].
Echocardiography on day 7 after exosome treatment revealed improved ejection
fraction and fractional shortening as compared to control animals treated with
phosphate-buffered saline. Molecular mechanisms revealed significantly abrogated
expression of pro-inflammatory factors including IL-6, IL-10, and TNF.
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Use of exosomes as delivery vehicles for miRNA
Extending further, exosomes have been directly modified for their payload for use
as carriers of miRs for delivery to the target cells due to their ability to transfect a
wide variety of cells. Their potential to transfect various cell types is being equated
with viral vectors for their application as nano-size theranostic delivery platforms
for miRs [123]. In addition to their privileged transfection efficiency, exosomes are
less cytotoxic, low in immunogenicity, and more compatible than the cells from
which they have been derived [124]. In this regard, MSCs are being tipped as the
ideal cells for mass-scale exosome production for subsequent engineering to deliver
miRs of interest [125]. Protocols have been designed to engineer exosomes directly
with the payload of miRs by electroporation, lipofection, sonication, and calcium
chloride treatment. For example, MSC-derived exosomes have been successfully
loaded to carry miR-132 mimics by electroporation. The miR-132-loaded exosomes
were then incubated with HUVECs to upregulate miR-132 in the recipient cells
which showed higher angiogenic potential during matrigel plug angiogenesis assay
in vitro and post-transplantation in a murine model of acute MI [121]. On the same
note, plasma-derived exosomes from healthy donors were engineered to carry miR-
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31 and miR-451b with anti-tumor activity. Subsequent treatment of hepatocellular
carcinoma cells with exosomes loaded with miR-31 and miR-451b significantly
enhanced their apoptosis by suppressing anti-apoptotic signaling pathways [126].
Given the successful use of exosomes as vehicles for miR payload delivery,
exosome mimics are being developed for delivery of miR payload of interest which
includes nano-vesicles generated by cell extrusion and the cell membrane cloaked
nanoparticles [127].
Conclusion and future perspective
The strategy of cell-free therapeutic intervention started with the earlier
observations that conditioned medium from genetically modified cells led to
improved cell survival and protected the infarcted heart [53, 54]. Since then,
favorable data in this regard have kept pouring in to show that the secreted
bioactive molecules are cytoprotective, anti-apoptotic, pro-proliferative, and
effective in preconditioning of stem cells to support their cardiomyogenic
differentiation [128, 129, 130]. Efforts are underway to develop a standard protocol
for bioprocessing and quality control of the conditioned medium for optimal
therapeutic usage [131]. The exosome-based strategy is fast-emerging as an
alternative to the conditioned medium-based cell-free therapy approach [132].
Either way, the intent of cell-free therapy is to support the intrinsic repair
mechanism of the heart rather than treatment with stem cells from exogenous
source (Fig. 2). In addition to the other attributes, cell-free therapy could be
rendered logistically more favorable by freeze-drying the secretome for ready-to-
use off-the-shelf availability that makes it clinically more relevant [133].
Fig. 2





The exosomal payload plays a significant role in the pathophysiology of IHD
including endothelial cell function, lipid deposition and plaque formation, and
ischemia-reperfusion injury by constituting an integral part of the intercellular
communication. These exosomes are released by a diverse population of cells
including endothelial cells, cardiomyocytes, and smooth muscle cells which are
participating in the disease process as shown in Table 1 [134, 135]. The exosomal
miRs released by these cells, as well as by the inflammatory cells homing-in to
injured myocardium, also play a significant role in the acute phase inflammatory
response as part of the intrinsic repair process in the heart [134]. This necessitates
in-depth future studies to develop protocols to ensure that the exogenously
delivered exosomes could deliver their miR payload without getting eliminated
from the site of injury by the inflammatory cells. It is pertinent to mention that the
payload of the released exosomes, including the miR contents, has a dynamic
nature, as it keeps changing in response to the microenvironmental factors. Hence,
there is as yet no well-defined miR profile available and there are no optimally
defined conditions to culture MSCs and reproducibly harvest clinically effective
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exosomes [136]. Akin to the quality of the donor cells as determinant of the
outcome of cell therapy procedure, it is imperative to establish a relationship
between the therapeutic effectiveness of exosomes released by various qualities of
the cells in culture. Various research groups are currently engaged in optimizing
protocols to pack exosomes with therapeutically effective well-defined payload of
miRs [137, 138]. A step forward is the use of induced pluripotent stem cells
(iPSCs) derived MSCs as a renewable source of exosomes [139]. Another important
step forward would be to enhance exosomal tropism for the cardiomyocytes [140].
The expression of the cardiomyocyte-specific peptide on the exosomal surface may
improve homing-in of the delivered exosomes and promote their fusion with the
recipient cardiomyocyte membrane as a mechanism for the delivery of their miR
payload via endocytosis. As in vivo biodistribution of the delivered exosomes is
determined by the route of administration [141], future studies would be required to
ascertain the effectiveness of various routes of exosome administration in general
and intracoronary (I/C) delivery in particular as I/C administration exosomes have
been reported as less efficacious in large animal models [142]. On the same note, it
is imperative to understand that the acute phase inflammatory response in the
infarcted heart, as part of the intrinsic repair process, immensely reduces the
efficacy of cell-based therapies as well as exosome-based intervention.
Table 1
Exosomal miRs released from various cell types [134, 135]
AQ14
Cell type Exosomal miRs released
Endothelial cells miR-10, miR-143/145, miR-214, miR-342-5p
Smooth muscle cells miR-155, miR-221/222
Cardiomyocytes miR-30a, miR-320
Cardiac fibroblasts miR-27a, miR-28a, 34a
In conclusion, therapeutic benefits of cell therapy are being attributed to the donor
cell-derived paracrine factors as well as extracellular vesicles which are loaded with
various biologically active components including miRs. As the quality of these
secretions of MSCs is amenable to various physical and genetic modulation
strategies, future studies should be focused on the bioengineering of cells which
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